Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MEREO BIOPHARMA GROUP PLC

(MREO)
  Report
Delayed Nasdaq  -  04:00 2022-10-06 pm EDT
0.9432 USD   -2.28%
10/04European ADRs Climb in Tuesday Trading
MT
10/03Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
GL
10/03Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Adjusts Price Target on Mereo BioPharma Group to $5 From $10, Reiterates Buy Rating

06/06/2022 | 07:18am EDT


© MT Newswires 2022
All news about MEREO BIOPHARMA GROUP PLC
10/04European ADRs Climb in Tuesday Trading
MT
10/03Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Me..
GL
10/03Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Me..
CI
10/03European ADRs Surge Higher in Monday Trading
MT
10/03Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees..
BU
09/27European ADRs Climb Higher in Tuesday Trading
MT
09/26Mereo BioPharma Says Rubric Capital Management Rejected Offer to Resolve Proxy Contest
MT
09/26Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putti..
AQ
09/23Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders
CI
09/22European ADRs Move Lower in Thursday Trading
MT
More news
Analyst Recommendations on MEREO BIOPHARMA GROUP PLC
More recommendations
Financials
Sales 2022 - - -
Net income 2022 -38,6 M -43,1 M -43,1 M
Net Debt 2022 - - -
P/E ratio 2022 -12,6x
Yield 2022 -
Capitalization 91,6 M 102 M 102 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 49
Free-Float 51,6%
Chart MEREO BIOPHARMA GROUP PLC
Duration : Period :
Mereo BioPharma Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEREO BIOPHARMA GROUP PLC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 84,30 GBX
Average target price 523,80 GBX
Spread / Average Target 521%
EPS Revisions
Managers and Directors
Denise Vera Scots-Knight Chief Executive Officer & Director
Christine Fox Chief Financial Officer
Michael S. Wyzga Chairman
John A. Lewicki Chief Scientific Officer
Suba Krishnan Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MEREO BIOPHARMA GROUP PLC-41.05%102
REGENERON PHARMACEUTICALS, INC.15.89%78 242
VERTEX PHARMACEUTICALS35.99%76 586
BIONTECH SE-46.65%33 422
WUXI APPTEC CO., LTD.-39.54%29 123
GENMAB A/S5.32%23 876